NeOnc Technologies Holdings, Inc. Common Stock NTHI
$4.73
+0.42%
at last close
Market Cap$122.16 million
P/E Ratio—
Div Yield—
Volume6.6K
52-Week Range
$3.00$12.99
Analyst Ratings
- Consensus
- Buy — 3 Buy · 0 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $16.00 (+238.3% upside)
Key Stats
- Today's Range
- $4.67 – $4.77
- 50-Day Range
- $3.00 – $5.82
- 52-Week Range
- $3.00 – $12.99
- Volume
- 7K shs
- Average Volume
- 203K shs
- Market Cap
- $122.16 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -6.59
- Price / Sales
- —
Short Interest
- Short Interest
- 0.03%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-47,200,000
- Net Margin
- —
- Return on Equity
- 254.73%
- Debt-to-Equity
- —
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
Related Stocks
Compare head-to-head: NTHI vs LLY·NTHI vs JNJ·NTHI vs ABBV·NTHI vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.